Study on antibody-conjugated drugs and targeted therapy for triple-negative breast cancer

Abstract. Statistics show that, second only to lung cancer, breast cancer is now the most common type of cancer worldwide. Compared to other forms of breast cancer, triple negative breast cancer (TNBC) has a worse prognosis, extensive metastases, and poor efficacy, making treatment more difficult. antibody-drug conjugates (ADCs), have become a hot topic in targeted tumor therapy research. Gosa tuzumab is the first drug approved for advanced TNBC treatment globally. However, challenges remain in the clinical use of ADCs, such as limited delivery of ADCs to target cells and suboptimal anti-tumor effects. This article analyzes targeted therapy methods and ADCs for TNBC, summarizes current market gosa tuzumab and ongoing clinical trials for ADCs drugs, providing a reference for further study on TNBC treatment with ADCs. Nevertheless, issues like drug resistance, adverse reactions and combination strategies with other chemotherapy inhibitors for TNBC treatment warrant further investigation in future clinical trials.